November 26, 2024

The Listing Department Dept. of Listing Operations

National Stock Exchange of India Limited BSE Limited,
Exchange Plaza, 5th Floor, Plot No. C/1 P J Towers, Dalal Street,
G Block, Bandra-Kurla Complex, Bandra (E) Mumbai -400001, India
Mumbai – 400 051

Symbol: YATHARTH Scrip Code: 543950

Dear Sir/Ma’am,

Sub:- Corporate presentation November 2024.

Please find enclosed Corporate Presentation for November 2024 pursuant to Regulation 30 of
the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015.

Kindly take the same in your records.

Thanking you,

Your faithfully,
For Yatharth Hospital and Trauma Care Services Limited

Ritesh Mishra
Company Secretary & Compliance Officer
Enclosed: As above
Corporate Presentation
November 2024
Disclaimer
This presentation has been prepared for general information purposes in respect of Yatharth Hospital and Trauma Care Services Limited (“Company”) together with its subsidiaries (together, with the Company, the “Group”) only, without regard to
any specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation or form part of any offer or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or
any solicitation of any offer to purchase or subscribe for, any securities of the Company in any jurisdiction, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment
therefor. This presentation does not solicit any action based on the material contained herein. Nothing in this presentation is intended by the Group to be construed as legal, accounting or tax advice.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India.

This presentation contains certain forward-looking statements relating to the business, financial performance, strategy and results of the Group and/ or the industry in which it operates. Forward-looking statements are statements concerning
future circumstances and results, and any other statements that are not historical facts, sometimes identified by the words including, without limitation “believes”, “expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”,
“anticipates”, “targets”, and similar expressions. The forward-looking statements, including those cited from third party sources, contained in this presentation are based on numerous assumptions and are uncertain and subject to risks. A
multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Neither the Group nor its affiliates or
advisors or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either
accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. Forward-looking statements speak only as of the date of this
presentation and are not guarantees of future performance. As a result, the Group expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any
change in expectations or any change in events, conditions, assumptions or circumstances on which these forward looking statements are based. Given these uncertainties and other factors, viewers of this presentation are cautioned not to
place undue reliance on these forward-looking statements. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an
arithmetic aggregation of the figures that precede them.

The information contained in these presentations and materials are only current as of the dates specified herein and have not been independently verified. None of the Group, its directors, promoter or affiliates, nor any of its or their respective
employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss,
cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise in connection with this presentation, and makes no representation or warranty, express or implied, for the
contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation
shall be relied upon as a promise or representation in this respect, whether as to the past or the future. Past performance is not a guide for future performance. The information contained in this presentation is current, and if not stated otherwise,
made as of the date of this presentation. The Group undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

Any person/ party intending to provide finance/ invest in the shares/ businesses of the Group shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an
informed decision.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been
obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party
sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective
judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

2
Disclaimer
This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and
Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India, nor does it form part of, and should not be construed as, any present or future invitation, recommendation or offer to purchase or sell securities of the
Company or an inducement to enter into investment activity in any jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment
decision whatsoever. If there is any subsequent offering of any security of the Company, it will be made pursuant to a separate and distinct offering documentation. Any decision to purchase securities in the context of an offering of securities (if
any) should be made solely on the basis of information contained in the offering documentation published in relation to such offering.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose. Any
unauthorized use, disclosure or public dissemination of information contained herein is prohibited. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given
or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. Neither this document nor any part
or copy of it may be distributed, directly or indirectly, in the United States. The distribution of this document in certain jurisdictions may be restricted by law and persons in to whose possession this presentation comes should inform themselves
about and observe any such restrictions. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions. By reviewing this presentation, you agree to be bound by the foregoing
limitations. You further represent and agree that you are located outside the United States and that you are permitted under the laws of your jurisdiction to receive this presentation. You may not repackage or sell the presentation.

Information contained in a presentation hosted or promoted by the Group is provided “as is” without warranty of any kind, either expressed or implied, including any warranty of fitness for a particular purpose.

This presentation is not an offer to sell or a solicitation of any offer to buy the securities of the Company in the United States or in any other jurisdiction where such offer or sale would be unlawful. Securities may not be offered, sold, resold, pledged,
delivered, distributed or transferred, directly or indirectly, in to or within the United States absent registration under the United States Securities Act of 1933, as amended (the “Securities Act”), except pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Company’s securities have not been and will not be
registered under the Securities Act and no public offering of securities will be made in the United States.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.

By accessing this presentation, you accept this disclaimer and any claims arising out of or in connection with this presentation shall be governed by the laws of India and only the courts in the concerned state in India and no other courts shall
have jurisdiction over the same.

3
Overview
 Super specialty hospital in North India
One-stop destination for patient needs providing all levels of
7 10 87% healthcare services from primary to tertiary
Hospitals(1) Center of Excellence Beds in Metros(1)

2019
Noida Extension
2024
450 beds
Model Town, Delhi
~300 beds
2013
2,300+ Rs. 30,597 61%
Bed Capacity (1) ARPOB (2) (H1FY25) Occupancy (H1FY25)
Noida
2024 250 beds
Faridabad
~400 beds
2010
Greater Noida
2024 400 beds
Gr. Faridabad
200 beds Rs. 6,705 mn 26.8% 17.1%
Revenue (FY24) EBITDA Margin(3) (FY24) PAT Margin(4) (FY24)

2022
Jhansi-Orchha
305 beds
29% 27% 27%
Revenue CAGR (5) EBITDA CAGR (5) ROCE(6) (FY24)
(FY22-24) (FY22-24)

Upcoming Hospitals

Notes: 1) As of September 30, 2024 and Includes upcoming hospitals in Delhi & Faridabad which has bed capacity of 300 beds & 400 beds respectively; 2) ARPOB (Average Revenue per Occupied Bed) = Revenue from operations
5/ Total occupied beds; 3) EBITDA Margin = EBITDA / Revenue from operations; where EBITDA = Profit Before Tax + Finance Cost + Depreciation Cost – Other Income; 4)
PAT Margin = Profit after tax / Revenue from operations; 5) 5
CAGR = Computed Annual Growth Rate; 6) ROCE (Return on Capital Employed) = EBIT / Avg. Capital Employed; where Capital Employed = Gross Debt (including lease liabilities)+ Networth – Cash & Cash Equivalent
 Our Journey
Growing presence across regions and services

Established our first Expansion of our first Acquisition of 4th hospital - Acquired 5th hospital –
hospital in Greater hospital, Greater Noida Jhansi Orchha hospital 200 beds in Gr. Faridabad;
Noida hospital, to 400 beds adding 305 beds, pursuant to 6th & 7th hospital being
acquisition of subsidiary, acquired in Delhi &
Ramraja Faridabad

2008 2010 2013 2018 2019 2022 2023 2024

Incorporation of Established our Commencement of our third Listing on NSE & BSE
company and second 250 bedded hospital, Noida Extension
commencement of hospital, in Noida hospital, in May 2019,
operations pursuant to the acquisition of
subsidiary AKS in 2016

6 Acquisitions
6
 Our Hospitals
Built on foundation of talent, trust, technology, service and infrastructure

Diversified revenue mix Greater Noida Jhansi - Greater

across hospitals Hospitals Noida
Noida
Extension Orchha Faridabad
(H1 FY25)

Year of Operation 2010 2013 2019 2022 2024

Faridabad
Jhansi- 3%
Beds Capacity 400 250 450 305 200
Orchha
6%
Greater Noida
32% No of ICU Beds 112 81 125 76 61

Noida
22% Occupancy Rate 66% 83% 60% 47% 28%*
Noida
Extension
37% ARPOB(1) (Rs.) 34,444 28,732 37,727 12,397 28,598

ALOS(2) 4.49 5.15 4.36 3.82 3.27

All figures for H1 FY25

Notes: *Given gradual ramp up in bed capacity at Faridabad, the utilization has been computed on 100 beds; 1) ARPOB (Average Revenue per Occupied Bed) = Revenue from operations / Total occupied beds; 2) ALOS (Average
length of stay) – Total occupied beds / Inpatient Volume
7
 Our Hospitals

66% Occupancy
Greater Noida Provides a wide spectrum of super specialty services in the field of
2010 Incorporated Rs.34,444 ARPOB (1) cardiology, cardiovascular and thoracic surgery, neurology,
400 Beds; 112 ICU Beds neurosurgery, urology, nephrology, oncology, gastroenterology etc.

4.49 days ALOS (2)

83% Occupancy
Noida Provides services across 30 specialties, including cardiac sciences,
Rs.28,732 ARPOB (1) orthopedics, nephrology, urology, neurosciences, gastroenterology,
2013 Incorporated
etc.
250 Beds; 81 ICU Beds
5.15 days ALOS (2)

Super specialties contribute c. 70% of overall business; continued

60% Occupancy efforts to develop this hospital as Centre of Excellence for oncology

Noida Extension and robotic surgeries. In Mar’24, radiation oncology line was
inaugurated to provide comprehensive suite of oncology
2019 Incorporated Rs.37,727 ARPOB (1) treatments

Accredited by Joint Commission International (JCI) – Noida

450 Beds; 125 ICU Beds extension hospital received JCI accreditation,
4.36 days ALOS (2) 1st in UP & 7th in North India to achieve this accreditation. Amongst
few hospitals to get JCI accreditation in first instance

All figures for H1 FY25

8Notes: 1) ARPOB (Average Revenue per Occupied Bed) = Revenue from operations / Total occupied beds; 2) ALOS (Average length of stay) – Total occupied beds / Inpatient Volume 8
 Our New hospitals

47%
Jhansi – Occupancy
Hospital in Jhansi-Orchha-Gwalior region, has

Orchha
infrastructure to operate all the major super specialties
Rs.12,397
ARPOB(1)
2022 Acquisition Acquired in FY22
305 Beds; 76 ICU Beds

3.82 days
ALOS(2)

28% Built 3 years ago with latest facilities on a 1.25-acre land

Greater Occupancy*
with NABH accreditations and empanelment with all

Faridabad Rs.28,598
major insurance/TPAs in place

2024 Acquisition ARPOB(1)

200 Beds; 61 ICU Beds Operationalized on May 12, 2024, expanding Yatharth’s
presence in North India
3.27 days
ALOS(2)

All figures for H1 FY25

9Notes: *Given gradual ramp up in bed capacity at Faridabad, the utilization has been computed on 100 beds; 1) ARPOB (Average Revenue per Occupied Bed) = Revenue from operations / Total occupied beds; 2) ALOS (Average 9
length of stay) – Total occupied beds / Inpatient Volume
 Operational Parameters
Occupancy (%) IPD/OPD Revenue (Rs. Mn)
IPD Revenue OPD Revenue
6,705
5,203 819
4,009 4,296
684
61% 506
50% 54% 546
45%
5,886
4,519 3,790
3,464

FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25

ARPOB(1) (Rs.) ALOS(2) (days)

28,571 30,597
23,511 26,538
5.20
4.78
4.32 4.42

FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25

Notes: 1) ARPOB (Average Revenue per Occupied Bed) = Revenue from operations / Total occupied beds; 2) ALOS (Average length of stay) – Total occupied beds / Inpatient Volume 10
 Financial Performance

Revenue (Rs. Mn) EBITDA(1) (Rs. Mn) & EBITDA%(2) 1800

PAT (Rs. Mn) & PAT%(3) 21%

20%

19%

1600

18%
2300
2295 30%
2290
2285
2280
2275
2270
2265
2260
2255
2250
2245
2240
2235
2230
2225 29%
2220
2215
2210

12.6% 17.1%
2205
2200

11.0%
17%

14.3%
219 5

27.6% 25.7% 25.2%

219 50

26.8%
218
218 0
2175
2170
216
216 5
0
215
215 5
0 28%
214
214 5
0
2135
2130
2125
2120
2115
2110 1400
210
210 50
2095
2090
2085
2080
2075
2070 27% 16%
2065
2060
2055
2050
2045
2040
2035
2030
2025
2020
2015
2010
2005
2000
1995
1990 26%
1985
1980
1975
1970
1965
1960
1955
1950
1945
1940 15%
1935
1930
1925
1920 25%
1915
1910
1905
1900
1895
1890
1885
1880
1875
1870
1865
1860
1855
1850
1845
1840 24%
1835
1830
1825
1820
1815
1810 120 0 14%
1805
1800
1795
1790
1785
1780
1775
1770
176
176 50 23%
1755
1750
1745
1740
1735
1730
1725
1720
1715
1710
1705
1700
1695
1690 22%
1685
1680 13%
1675
1670
1665
1660
1655
1650
1645
1640
1635
1630
1625
1620
1615
1610 21%
1605
1600
1595
1590
1585
1580
1575
1570
1565
1560
1555
1550 12%
1545
1540
1535
1530 20%
1525
1520
1515
1510 1000
1505
1500
1495
1490
1485
1480
1475
1470
1465
1460 19%
1455
1450
1445
1440
1435
1430
1425
1420 11%
1415
1410
1405
1400
1395
1390
1385
1380 18%
1375
1370
1365
1360
1355
1350
1345
1340
1335
1330
1325
1320
1315
1310
1305
1300 17%
129
129 55
0 10%
128
128 0
1275
1270
126
126 5
125 0
125 5
0
124
124 5
0
1235
1230 16%
1225
1220
1215
1210
120
120 5
0 80 0
119 5
119 5
0
118
118 0
1175
1170
116
116 5
0 9%
115
115 5
0 15%
114
114 5
0
1135
1130
1125
1120
1115
1110

6,705
110
110 5
0
1095
1090
1085
1080
1075
1070 14%
1065
1060
1055
1050
1045
1040
1035
1030 8%

1,799
1025
1020
1015
1010
1005
1000 13%
99 5

1,145
99 5
98 0
98
975 0
970
96 5
96
95 05
95
94 0
5
94
935 0
930
925
920
915 12%
910
90 5 60 0 7%

5,203
90
89 0
5
89 5
88 0
88
875 0
870
86 5
86
85 0
85 5
84 0
5 11%
84
835 0
830
825
820
815
810
80 5
80 0

1,338
795
790
785
780

4,296
775
770 10% 6%
765
760
755
750
745
740

4,009
735
730
725
720
715
710
705
700
69
69 5
0 9%
68 5

1,108
68
675 0

1,083
670
66 5
66
65 0
5
65
64 0
5 5%
64
635 0
630
625

658
620
615 8%
610
60 5 40 0
60
59 0
5

613
59 5
58 0
58
575 0
570
56 5
56
55 05
55
54 0
5
54
535 0 7%
530
525
520
515 4%
510
50 5
50
49 0
5
49 5
48 0
48
475 0
470
46 5

442
46
45 05 6%
45
44 0
5
44
435 0
430
425
420
415
410
40 5
40
395 0
390
385 5% 3%
380
375
370
365
360
355
350
345
340
335
330
325
320
315
310
305 4%
300
295 200
290
285
280
275
270
265
260
255 2%
250
245
240
235
230
225 3%
220
215
210
205
200
195
190
185
180
175
170
165
160
155 2%
150
145
140
135
130
125 1%
120
115
110
105
100
95
90
85
80
75 1%
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0 0% 0 0%

FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25

ROCE(4) & ROE(5) (%) Gross Block(6) (Rs. Mn) 130

125
Net Working Capital Days(7)
120

Capex per bed

115

110

ROCE ROE 105

3.72 3.07 3.90 4.40

100

95

90

750 0 4.5 0 85

80

4.0 0 75
650 0

70

3.5 0 65

550 0

112
60

104
3.0 0 55

45% 44%
450 0
50

7,062
2.5 0 45

6,260 68
350 0 40

27% 28% 29% 64

2.0 0 35

22% 23% 4,319

30

4,090
250 0

1.5 0 25

14% 150 0

1.0 0
20

15

10

500
0.5 0 5

FY22 FY23 FY24 H1FY25

-500 0.0 0

FY22 FY23 FY24 H1FY25 FY22 FY23 FY24 H1FY25

Notes: 1) EBITDA = Profit Before Tax + Finance Cost + Depreciation Cost – Other Income; 2) EBITDA % = EBITDA / Revenue from operations; where EBITDA = Profit Before Tax + Finance Cost + Depreciation Cost – Other Income; 3)
PAT Margin = Profit after tax / Revenue from operations; 4) ROCE = EBIT / Avg. Capital Employed for current period and previous period; where Capital Employed = Gross Debt (including lease liabilities)+ Networth – Cash & Cash
11
Equivalent; 5) ROE (Return on Equity) = PAT / Avg. Equity for current period and previous period; 6) Gross Block = Gross Property, Plant & Equipment + Right-of-use assets; 7) Working capital days is calculated as working capital *
11
365 divided by revenue from operations, where Working capital refers to current assets minus current liability
 Peer Comparison
29.17%
24.56% 22.65% 22.54% 21.91% 20.32%
Revenue 16.33% 14.57% 13.96%
10.39%
CAGR
(FY 22-24)
Aster Medanta KIMS Jupiter Paras Narayana Max Apollo Fortis

27.80% 26.83% 25.64% 25.29% 24.11% 22.96%

18.39%
15.62%
OPBDIT 12.54%
10.54%
Margin(1)
(FY24)
Max KIMS Medanta Jupiter Narayana Fortis Aster Apollo Paras

36.82%
28.93%
25.90%
21.74% 21.47% 21.40% 20.64% 19.95%
ROCE(2) 11.34%
FY24
NA

Max Narayana Jupiter Fortis Medanta KIMS Apollo Paras Aster

Source: CRISIL Industry Report

Notes: 1) OPBDIT Margin: OPBDIT / Revenue from operations; where OPBDIT = Operating Profit before Depreciation, Interest & Tax; 2) ROCE = Profit before Interest & tax (PBIT)/(Avg. total debt + avg. tangible networth + avg.
deferred tax liability)
12
 Experienced board and leadership team
Promila Bhardwaj
Dr. Ajay Kumar Tyagi Independent Director
Chairman & Whole-time Director
35+ yrs of experience
17+ yrs of experience Bachelor of arts, Master’s of arts in English, philosophy in social
Bachelor of medicine, surgery, and diploma in orthopaedics sciences and diploma in public administration
Board of Directors

Dr. Kapil Kumar Mukesh Sharma

Managing Director Independent Director
17+ yrs of experience 35+ yrs of experience
Bachelor of medicine, surgery, and master of orthopedic Bachelor’s in science agriculture & animal husbandry
surgery, Magister chirurgie in orthopedics MBA; Post graduate diploma in labour law & welfare, & personnel
management
Bachelor’s of law

Yatharth Tyagi
Sanjeev Upadhyaya
Whole-time Director
Independent Director
Bachelor’s in business management from Leeds Beckett
20+ yrs of experience
University
Bachelor’s in medicine, surgery
Master’s of science in International Health Management from
Doctor of medicine in community medicine
Imperial College, London
KMPs

Amit Kumar Singh Nitin Gupta Pankaj Prabhakar Neeraj Vinayak Sonu Goyal
Chief Executive Officer COO & President - Finance Chief Financial Officer Head, Strategy & Investor Relations Group Finance Controller

13
Industry
Overview
 Healthcare Delivery Market in India is at Nascent stage
Indian hospital market to grow at a CAGR of 10-12% to reach INR 10tn by FY28 Globally India has one of the lowest bed density/10,000 population

70
(INR tn)
50
9.4-9.8
27
6.3 2.6 26

3.9 1.8 25
1.3 7.2 24
4.5
2.6 20
FY19 FY24E FY28P 15
IPD OPD 9 World Average: 33

Hospitals constitute the largest share of the healthcare market in India Pvt. hospitals share is expected to increase 70% by FY28P

30%
9% Hospitals 33%
9%
Domestic Pharmaceuticals FY24 E FY28 P
20% FY24 E 67%
62% Diagnostics
70%

Medical Devices

Private Hospitals Government Hospitals

Source : Crisil Report

15
 North India - Underserved market with huge growth potential

North India hospital market is expected to grow at a CAGR of 12-14%... …Growing at a faster rate than the overall industry
(INR tn) (INR tn)
9-11% 10-12%
3.9 6.3 9.4-9.8
3.1-3.2 10-12% 11-13%
22.5-23.5% 22-24% 22-25%
9-11% 10-12%
11.5-12.5% 10.5-12.5% 10-13%
1.9-2.0

35-36% 9-11% 34-36% 9-11% 32-35%

1.1-1.5

10-12% 12-14% 30.5-33.5%

29-30% 29.5-31.5%

FY19 FY24E FY28P FY19 FY24E FY28P

North South East West

Low concentration of private chains in North India Bed density of Delhi-NCR is below WHO recommendations
Total hospital beds (‘000)

20-21 6-6.5 110-115 295-300 64-66 44-46 40-42

Total beds per 10,000 population WHO Recommendation
Beds of private chains as a % of total beds (2022) 43
40
36
0-1% 14-15% 18-19% 33
1-2% 2-3% 2.5-3.5% 4.5-5.5% 27
Punjab

Delhi
Rajasthan

UP
HP

Chandigarh

Haryana

Chennai

Bengaluru
Delhi NCR

Mumbai

Hyderabad
Source : Crisil Report
16
Growth
Strategy
Core strategies driving growth
Optimizing Infrastructure
Enhancing occupancy and ARPOB across our hospitals
01

Capacity Addition
02 Greenfield and brownfield expansion

Leverage Technology
03 Advanced and high-end medical equipment
and technology

04
Clinical Expertise
Attracting best talent to drive super specialties

Optimizing
Capacity Expansion Leverage Technology Clinical Expertise 18
Infrastructure
 Optimizing existing infrastructure

Mature hospitals New hospitals Total

Occupancy (%)

67%
63% 61%
55% 54%
50% 50% Improve
45% 42% Diversifying
customer
specialties
service
23%

8%
NM

FY22 FY23 FY24 H1FY25

Our 5-fold
approach to
optimize
34,049 existing infra
29,646 30,597 Optimized Enhanced care
28,571 scheduling
26,886 26,538 coordination
23,511 23,511
ARPOB (Rs)

17,692 14,935
17,429

NM

FY22 FY23 FY24 H1FY25 Expand Services

Optimizing
19 19
Infrastructure
 Expanding specialties across hospitals

Diverse mix of specialties at all hospitals Noida extension hospital registered

highest share of super specialties

H1
21% 12% 10% 10% 10% 8% 7% 6% 5% 4% 3%
FY2025 Pediatrics
3% Oncology
Pulmonology
18%
5%
Gynecology
5%
FY2024 28% 10% 4% 10% 10% 7%
Orthopedics, Spine
& Rheumatology Internal
7% Noida Ext. Medicine
12%
Gastroenterology H1 FY25
FY2022 50% 7%

General Surgery
Internal Medicine Neurosciences
7%
Nephrology & Urology
Oncology Cardiology
12%
Nephrology & Urology General Surgery Neurosciences
8% Cardiology
Pulmonology Orthopedics, Spine & Rheumatology
11%
Gastroenterology Gynecology
Pediatrics Others

Optimizing
Infrastructure 20
 Capacity addition - greenfield and brownfield expansion
Capacity addition trend and roadmap ahead

Operational Beds New bed addition Current Bed Capacity

Acquired in
Acquired in Oct-24
May-24 Oct-24
Apr-22
May-19

• Acquired super specialty hospital in Model Town, New Delhi, with an expandable capacity of 300+ beds, through e-
auction under SARFAESI Act 2002 in Oct-24
• Entered in strategic collaboration agreement to acquire majority (~60%) stake in yet to commence ~400 bedded-
hospital in Faridabad, Haryana

21 Capacity Expansion 21
 Expanding footprints in New Delhi market, with ~300 beds

Established Multi-specialty hospital

Established in 2019

Expandable to 300+ Beds

❖ Successful bid for MD City Hospital in Delhi

through the e-auction process under the
Acquisition Cost ~Rs. 160 crore SARFAESI Act, 2002

❖ The hospital cater a large catchment of

residential and institutional client base in the
region
Located in Model Town, New Delhi

22 Capacity Expansion 22
 Acquiring majority stake in 400-bedded Faridabad hospital

Yet to commence Multi-specialty hospital

Built on approx. 2 Acre land

Proposed Capacity 400 Beds ❖ Strategic collaboration agreement for ~60% stake
acquisition in ~400 bed-hospital in Faridabad

❖ Hospital valued at enterprise value of Rs. 152 crore

Majority stake being acquired Rs. 91 crore ❖ Acquisition positions Yatharth as one of the largest
bed capacity in the region

❖ Hospital’s structure is completed - plans to equip

latest advanced medical equipment & provide
Located in Sec-20, Faridabad, Haryana super specialty services, including full suite of
oncology treatments and robotic surgeries

23 Capacity Expansion 23
 Advanced medical equipment and technology
• Hospitals are equipped with machines and devices with sophisticated technology
• Strive to introduce medical technology and state-of-the-art equipment

Complex Kidney, Liver & Bone Robotic Surgeries –

Marrow Transplant DaVinci, Mako & Cuvis Radiation Oncology
procedures
Presence in Noida Ext & Noida Ext, Greater Noida Extension
Hospitals Greater Noida Noida & Faridabad

No. of procedures
200+ 500+ 1,000+
performed till date

• Catheterization Laboratory
• We have NABH certificates for all other hospitals
• Computerized Tomography Scan (CT Scan)
Diagnostic except Faridabad & Jhansi. We have applied for
• Magnetic Resonance Imaging (MRI) Certifications
Equipment the NABH certificate for Faridabad hospital.
• Imaging equipment - Mammography, Advanced
• We have NABL certification for all our hospitals
EEG, Nerve conduction velocity, advanced

+
except Jhansi and Faridabad
surgical equipment etc.

• Critical care units are equipped with patient

• Well-equipped modular and other operation monitoring devices, ventilators and dedicated
theatres with three stage air filtration and isolation rooms
laminar flow Operation • Facilities for haemodialysis, sustained low-
Critical care
• Operating microscopes, image intensifiers, and Theatres efficiency dialysis, endoscopy and bronchoscopy
laparoscopic equipment
Equipment
are available 24x7 by the bedside

24 Leverage Technology 24
Attracting talent to drive super specialties

Strategic initiatives
aimed to ease attrition
Integrating talent from First mover advantage in
allied workforce building out network across
Tier II/III cities
❑ Applied DNB program across 8
specialties in 2 of the hospitals
❑ DNB program to reduce attrition of
Resident Medical Doctors
❑ Total 27 resident doctors have joined the
DNB program till date

❑ Keep staff abreast with global

developments concerning the health
sector
Stronger local connect Promoters being doctors, ❑ Strive to provide better doctor visibility
with people have better connect with amongst the potential patients through
doctors marketing and awareness campaigns

Clinical Expertise 25
Annexures
Awards and Accreditations

2020 2021 2022 2023 2024

➢ Awarded 1st in ➢ Covid Thank You award ➢ 5-star grading by ➢ Awarded UP Ratan ➢ Awarded Best Brand for
Swachhta Ranking (for by Niva Bupa Infomerics Analysts & Samman by Dainik Excellence in Healthcare
quarter ended Sep 2019) ➢ Accreditation from NABH Research for our Jagran Inext at Economic Times (ET)
in Swachh Survekshan to the Noida Extension hospitals located at ➢ Accreditation (ISO Edge Best Brands
League 2020 by Noida Conclave, for consistent
Hospital Greater Noida 15189:2012) from NABL for
Authority innovation and
medical testing to the
➢ Recognized as Emerging customer-centricity
Noida Extension Hospital
Hospital Chain in Delhi ➢ Noida extension hospital
NCR by Medico Trip India accredited by Joint
➢ Accreditation (ISO Commission
15189:2012) from NABL for International (JCI) –
molecular testing being 1st in UP & 7th in
(RTPCR-Covid 19) for the North India to get this
Noida Extension Hospital accreditation
27
 Profit & Loss Summary

Particulars (Rs Mn) H1 FY25 FY24

Revenue from Operations 4,296 6,705

Medical Consumables & Pharmacy 900 1,333
Employee Expenses 761 1,170
Other Expenses 1,552 2,403
EBITDA 1,083 1,799
EBITDA Margin % 25.2% 26.8%
Depreciation and amortisation 274 293
Financial Cost 45 94
Other Income 66 156
Profit Before Tax (PBT) 831 1,568
Tax 217 424
Profit After Tax (PAT) 613 1,145
PAT Margin % 14.3% 17.1%

2
8 28
Balance Sheet

Particulars (Rs Mn) Sep-24 Mar-24 Particulars (Rs Mn) Sep-24 Mar-24

Shareholders Equity 9,323 8,743 Fixed Assets (incl. Goodwill) 5,090 4,405

Borrowings 896 831 Right to Use Assets 4 14

Lease Liabilities 5 16 Financial Assets 128 243

Trade Payables 289 292 Inventories 143 81

Other financial liabilities 294 253 Trade Receivables 2,587 2,270

Other liabilities 29 33 Cash & Bank Balances 2,442 2,386

Provisions 96 26 Other assets 539 794

Total Liabilities 10,933 10,193 Total Assets 10,933 10,193

29
Thank You
Yatharth Hospital & Trauma Care Services Ltd

Investor Relations Contact

Mr. Neeraj Vinayak, Head – Strategy and Investor Relations
investor.relations@yatharthhospitals.com

CIN: L85110DL2008PLC174706
www.yatharthhospitals.com